

Technology Guidance

Trastuzumab deruxtecan

**for unresectable or metastatic non-small-cell lung cancer
whose tumours have activating HER2 (ERBB2) mutations and
who have received a prior systemic therapy**

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended trastuzumab deruxtecan (T-DXd) for inclusion on the MOH List of Subsidised Drugs for treating patients with unresectable or metastatic non-small-cell lung cancer whose tumours have activating human epidermal growth receptor 2 (HER2) mutations and who have received a prior systemic therapy. The decision was based on the uncertainties in the clinical and cost effectiveness of T-DXd in the patient population, and an unacceptable pricing proposal by the company.

Clinical indication, subsidy class and MediShield Life claim limit for T-DXd are provided in the Annex.

Published: 6 February 2026

ANNEX

Recommendations by the MOH Drug Advisory Committee

Drug preparation	Company-proposed clinical indication	Subsidy class	MediShield Life claim limit per month
Trastuzumab deruxtecan powder for concentrate for solution for infusion 100 mg	Treatment of adult patients with unresectable or metastatic non-small-cell lung cancer whose tumours have activating HER2 (ERBB2) mutations and who have received a prior systemic therapy.	Not recommended for subsidy	Not recommended for MediShield Life claims

Abbreviations: ERBB2, erb-b2 receptor tyrosine kinase 2; HER2, human epidermal growth receptor 2.

 Agency for Care Effectiveness - ACE  Agency for Care Effectiveness (ACE)

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

The guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at www.ace-hta.gov.sg/about

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Agency for Care Effectiveness, Ministry of Health, Singapore
Email: ACE-HTA@moh.gov.sg

In citation, please credit "Agency for Care Effectiveness, Ministry of Health, Singapore" when you extract and use the information or data from the publication.